Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Apr 1.
Published in final edited form as: Am J Transplant. 2026 Mar 3;26(7):1724–1736. doi: 10.1016/j.ajt.2026.02.036

Population-level cancer trends among solid organ transplant recipients in the United States during 1995–2021

Eric A Engels 1, David Castenson 2, Qianlai Luo 1, Meredith S Shiels 1, Ajay Israni 3, Jie Li 4, Margaret M Madeleine 5, Karen Pawlish 4, Daniela Ramirez Aguilar 6, Yun Zeng 7, Ruth M Pfieffer 1
PMCID: PMC13037663  NIHMSID: NIHMS2159095  PMID: 41786253

Abstract

Solid organ transplant recipients (SOTRs) experience elevated cancer risk from immunosuppression and underlying medical conditions. Medical management has improved over time, and SOTRs are living longer. We used registry data covering 693,718 SOTRs in the United States (US) to evaluate population-level cancer trends during 1995–2021. Compared with SOTRs in 1995–2003, those in 2013–2021 were living at older ages and were followed at a longer time since their transplant. Based on 65,081 cancers, cancer incidence in SOTRs was higher during 2013–2021 than 1995–2003 (unadjusted incidence rate ratio [IRR] 1.29, 95% confidence interval [95%CI] 1.26–1.32). However, cancer incidence was lower in 2013–2021 after adjustment for age (IRR 0.93, 95%CI 0.91–0.95) and multivariable adjustment (0.93, 0.90–0.96). Results for the six most common cancer types showed varying trends during 1995–2021. Overall cancer incidence was higher in SOTRs than in the US general population during 1995–2021 and, most recently, in 2013–2021 (standardized incidence ratio 1.66, 95%CI 1.64–1.67). In conclusion, after accounting for age, there was an encouraging decline in cancer incidence among US SOTRs during 1995–2021. However, incidence remained elevated compared with the general population in 2013–2021. Measures are needed to reduce the cancer burden as SOTRs live longer after transplantation and the population ages.

Keywords: Solid organ transplant recipients, Cancer, Trend, Incidence rate, Standardized incidence ratio

Background

Solid organ transplant recipients (SOTRs) experience an elevated incidence of cancer, due to immunosuppression arising from medications used to prevent rejection, underlying medical conditions, and, potentially, directly carcinogenic effects of immunosuppressive medications (1–8). The spectrum of cancer risk in SOTRs is well documented (9, 10), encompassing an increased incidence for cancers caused by oncogenic viruses (e.g., non-Hodgkin lymphoma [NHL], which is part of the spectrum of posttransplant lymphoproliferative disorder caused by Epstein-Barr virus [EBV]). Incidence is also elevated for certain cancers unrelated to infections. For example, incidence of kidney and lung cancers is greatly elevated in recipients of those organs, due to the presence of native end-stage organs left in situ during transplantation (7, 8), but these cancers also arise at increased frequency in recipients of other organs (9). The incidence of breast and prostate cancers is not elevated among SOTRs (9, 10), although these cancers are nonetheless common.

Over the past few decades, there have been changes in treatment and survival among SOTRs that have likely influenced cancer incidence. First, with improvements in clinical management, SOTRs are living longer after a transplant (11–14), so they are aging, and they are experiencing prolonged cumulative exposure to immunosuppression and the possible genotoxic effects of medications. Second, there have been changes in immunosuppressant medications that may have impacted cancer risk. For example, during the early 2000s, there was a marked transition from maintenance regimens based on cyclosporine and/or azathioprine to ones based on tacrolimus and/or mycophenolate (which have somewhat improved side effect profiles) (15).

The population of SOTRs living with a transplant has thus changed over time. However, no study has systematically characterized calendar trends in cancer incidence among this evolving population. To address this gap, we used data from a large registry linkage study to evaluate population-level trends in cancer incidence among SOTRs in the United States (US) during 1995–2021. We compared the characteristics of the US SOTR population across three parts of this calendar period (1995–2003, 2004–2012, 2013–2021), assessing changes in major risk factors for cancer including age, time since transplant, and baseline immunosuppressant medications. We then evaluated how changes in the population over time may have contributed to the observed trends in cancer incidence. Finally, we compared cancer incidence in SOTRs to the US general population during the most recent period (2013–2021), to assess the degree to which cancer incidence remains elevated among SOTRs.

Methods

The Transplant Cancer Match (TCM) Study is a linkage of the US SOTR registry (the Scientific Registry of Transplant Recipients [SRTR]) with multiple US state and regional cancer registries (https://transplantmatch.cancer.gov) (9). At the time of this analysis, the TCM Study included data from 44 cancer registries covering approximately 87% of the US SOTR population (Supplementary Table 1). The study is not considered human subjects research by the National Cancer Institute but was approved, as required, by institutional review boards at participating cancer registries.

For the present study, we included SOTRs who lived in an area covered by a participating cancer registry at the time of transplant. We excluded SOTRs outside the four largest racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, Asian/Pacific Islander) to allow calculation of general population expected rates. For each transplant, follow-up started at the latest of the transplant date or January 1, 1995. Follow-up was censored at the earliest of death, graft failure/retransplant, end of cancer registry coverage, loss to follow-up by the SRTR, or December 31, 2021. For a person who received more than one transplant, their follow-up time was considered as comprising sequential periods (one for each transplant).

We used the linked cancer registry data to identify incident cancers diagnosed during follow-up. We assessed trends for all cancers combined as well as for the six most common types among SOTRs: cancers of the colorectum, lung, breast, prostate, and kidney, and NHL. Analyses of breast and prostate cancers were restricted to females and males, respectively.

We divided the overall cohort follow-up according to the following characteristics: sex, race/ethnicity, and age at first transplant; attained calendar year, attained age, and time since first transplant (corresponding to the SOTRs’ time-updated values as they progressed through follow-up); and transplanted organ, induction immunosuppressive treatment, and baseline maintenance regimen (updated during follow-up to reflect a person’s most recent transplant if they received multiple transplants over time). The characteristics of the follow-up time of this cohort are relevant in understanding their cancer risk, especially for factors such as attained age or time since first transplant that change over time. Thus, to describe how the SOTR population at risk of cancer changed over time, we calculated the proportion of the cohort follow-up time within each calendar year or 9-year period (1995–2003, 2004–2012, 2013–2021) corresponding to the other SOTR characteristics listed above.

We calculated crude cancer incidence rates as a measure of absolute risk in the two calendar periods. We then used Poisson regression models to analyze the associations between SOTR characteristics and cancer incidence. We focused on the association with calendar period (2004–2012 and 2013–2021, vs. 1995–2003), and we present three incidence rate ratios (IRRs) for this variable: unadjusted, adjusted only for attained age, or adjusted for sex, attained age, race/ethnicity, time since first transplant, transplanted organ, and induction and baseline maintenance medications.

To describe trends in more detail, we plotted age-standardized incidence rates for each cancer according to single calendar year, using the 2010 TCM transplant population as the age standard. These estimates are based on the attained ages of the SOTRs under follow-up in each calendar year. We used Joinpoint regression (https://surveillance.cancer.gov/joinpoint/) to identify significant changes in the slopes for these rate trends. Joinpoint also provided the annual percentage change in age-standardized incidence rates for each segment of calendar time between the change points.

We report standardized incidence ratios (SIRs) comparing cancer incidence in SOTRs to the general US population separately for each calendar period. These SIRs compare the observed number of cases in SOTRs to those expected based on incidence rates provided by 12 cancer registries in the Surveillance, Epidemiology, and End Results program (https://seer.cancer.gov/), stratified by sex, age, race/ethnicity, and calendar year.

Finally, because kidney cancer incidence increased over time, we conducted several additional analyses for this cancer. We examined trends according to stage at cancer diagnosis (localized vs. regional/distant), and separately for kidney-only recipients (i.e., SOTRs who had never received a non-kidney organ) and non-kidney recipients (i.e., SOTRs who had never received a kidney). In an analysis of recipients of a first kidney-only transplant, we characterized calendar trends in the duration of dialysis prior to transplant (i.e., dialysis vintage) and adjusted for this duration when comparing kidney cancer incidence across calendar periods.

Regression analyses were performed using SAS (version 9.4, SAS Institute). We considered a p-value of 0.05 to indicate statistical significance.

Results

Study population

We included 693,718 SOTRs (see Supplementary Table 1 for exclusions), who contributed 0.85 million person-years of follow-up during 1995–2003, 1.60 million person-years during 2004–2012, and 1.94 million person-years during 2013–2021. The increasing number of person-years of follow-up across the three calendar years reflects a growing number of transplants performed each year and an increasing number of survivors of prior transplants.

Table 1 describes the characteristics of this cohort as they were followed during the three calendar periods. Approximately 60% of the cohort follow-up was in males. Non-Hispanic White SOTRs were the largest group, but their contribution to cohort follow-up declined across the three periods. Age at transplant increased modestly over time, but a much larger difference was seen in attained age, with a growing proportion of the follow-up time among SOTRs at ages 60+ years (Figure 1A). Time since first transplant also increased over time, so that 32.9% of follow-up during 2021 was among SOTRs 10+ years after their first transplant (Figure 1B). The proportion of follow-up time among SOTRs treated with cyclosporine and/or azathioprine declined from 43.1% to 4.9% across the three periods, and the proportion of follow-up time among SOTRs treated with tacrolimus and/or mycophenolate increased from 31.6% to 84.3%. Finally, with respect to induction medications, the 2013–2021 period included more follow-up time among SOTRs treated with polyclonal antibodies (31.2%) and anti-interleukin-2 agents (21.2%), and fewer with only corticosteroids (16.4%), than in earlier periods.

Table 1.

Characteristics of the population of solid organ transplant recipients in the United States under follow-up during 1995–2021, according to calendar period

Overall period 1995–2021
Person-years of follow-up
% 1995–2003
Person-years of follow-up
% 2004–2012
Person-years of follow-up
% 2013–2021
Person-years of follow-up
%
Total 4,390,091 100 853,070 100 1,601,904 100 1,935,117 100
Sex
 Female 1,711,542 39.0 336,508 39.5 625,527 39.1 749,506 38.7
 Male 2,678,549 61.0 516,561 60.6 976,377 61.0 1,185,611 61.3
Age at first transplant, years
 0–9 21,6433 4.9 41,472 4.9 77,853 4.9 97,108 5.0
 10–19 189,305 4.3 40,648 4.8 69,213 4.3 79,445 4.1
 20–29 344,385 7.8 84,015 9.9 124,993 7.8 135,377 7.0
 30–39 624,600 14.2 153,091 18.0 23,0676 14.4 240,833 12.5
 40–49 960,393 21.9 214,042 25.1 363,010 22.7 383,341 19.8
 50–59 1,165,251 26.5 204,341 24.0 437,302 27.3 523,608 27.1
 60–69 766,636 17.5 105,993 12.4 258,680 16.2 401,963 20.8
 70+ 123,087 2.8 9,466 1.1 40,177 2.5 73,444 3.8
Race/ethnicity
 White, non-Hispanic 2,861,648 65.2 606,563 71.1 1,062,653 66.3 1,192,432 61.6
 Black, non-Hispanic 768,358 17.5 131,410 15.4 269,744 16.8 367,204 19.0
 Hispanic 553,536 12.6 85,585 10.0 197,382 12.3 270,569 14.0
 Asian/Pacific Islander 206,549 4.7 29,512 3.5 72,125 4.5 104,912 5.4
Transplanted organ*
 Kidney only 2,479,594 56.5 486,683 57.1 911,159 56.9 1,081,753 55.9
 Liver only 944,028 21.5 162,657 19.1 343,324 21.4 438,047 22.6
 Heart only 448,450 10.2 105,665 12.4 156,889 9.8 185,896 9.6
 Lung only 169,642 3.9 24,747 2.9 57,121 3.6 87,774 4.5
 Other/multiple 348,377 7.9 73,318 8.6 133,412 8.3 141,647 7.3
Calendar year of first transplant
 1987–1994 567,560 12.9 327,801 38.4 162,179 10.1 77,580 4.0
 1995–1999 821,242 18.7 391,446 45.9 296,551 18.5 133,245 6.9
 2000–2004 939,999 21.4 133,823 15.7 553,120 34.5 253,056 13.1
 2005–2009 936,776 21.3 0 0 494,630 30.9 442,147 22.9
 2010–2014 725,480 16.5 0 0 95,423 6.0 630,057 32.6
 2015–2021 399,033 9.1 0 0 0 399,033 20.6
Induction medication*
 None recorded 977,586 22.3 248,415 29.1 354,126 22.1 375,045 19.4
 Polyclonal antibodies (+/− corticosteroids) 1,146,576 26.1 149,742 17.6 392,465 24.5 604,369 31.2
 Anti-interleukin-2 antibodies (+/− corticosteroids) 816,035 18.6 83,482 9.8 322,472 20.1 410,081 21.2
 Corticosteroids only 959,966 21.9 270,259 31.7 371,740 23.2 317,967 16.4
 Other/multiple 489,927 11.2 101,172 11.9 161,100 10.1 227,655 11.8
Baseline maintenance regimen*
 None recorded 64,871 1.5 22,481 2.6 21,909 1.4 20,481 1.1
 Cyclosporine and/or azathioprine 678,544 15.5 367,659 43.1 215,988 13.5 94,897 4.9
 Tacrolimus and/or mycophenolate 2,955,362 67.3 269,855 31.6 1,054,177 65.8 1,631,330 84.3
 Other 691,313 15.8 193,074 22.6 309,830 19.3 188,409 9.7

Notes

*

These characteristics correspond to a person’s most recent transplant (if they had multiple transplants). The baseline maintenance regimens are categorized as cyclosporine and/or azathioprine (without use of tacrolimus or mycophenolate), tacrolimus and/or mycophenolate (without use of cyclosporine or azathioprine), other medications or combinations, or other.

Figure 1.

Figure 1.

Figure 1.

Proportion of the follow-up time among solid organ transplant recipients (SOTRs) in the United States during 1995–2021, by calendar year, according to attained age in years (panel A) or years since first transplant (panel B).

Cancer trends

A total of 65,081 cancers were observed during follow-up. Crude cancer incidence increased from 1,238 to 1,594 per 100,000 person-years between 1995–2003 and 2013–2021 (unadjusted IRR 1.29, 95% confidence interval [95%CI] 1.26–1.32). As shown in Table 2, attained age was also a strong cancer risk factor. In a regression model adjusted only for attained age, cancer incidence was lower in 2013–2021 than 1995–2003 (adjusted IRR 0.93, 95%CI 0.91–0.95; Table 3), and the result was similar in a full multivariable model (0.93, 0.90–0.96; Table 2). Additional factors independently associated with increased cancer incidence in the full model included male sex, receipt of a heart or lung transplant, longer attained time since first transplant, and maintenance immunosuppression with cyclosporine and/or azathioprine, while factors associated with lower cancer risk included Hispanic and Asian/Pacific Islander race/ethnicity, receipt of a liver transplant, and induction immunosuppression with anti-interleukin-2 antibodies (Table 2).

Table 2.

Risk factors for overall cancer among solid organ transplant recipients in the United States during 1995–2021

Characteristic Number of incident cancers Crude incidence rate, per 100,000 person-years Unadjusted IRR (95%CI) Multivariable adjusted IRR (95%CI)*
Attained calendar period
 1995–2003 10,560 1,238 1.00 1.00
 2004–2012 23,666 1,477 1.19 (1.17–1.22) 0.99 (0.96–1.02)
 2013–2021 30,855 1,594 1.29 (1.26–1.32) 0.93 (0.90–0.96)
Sex
 Female 20,860 1,219 1.00 1.00
 Male 44,221 1651 1.35 (1.33–1.38) 1.27 (1.25–1.3)
Attained age, years
 0–9 498 497 0.62 (0.57–0.68) 0.69 (0.62–0.75)
 10–19 635 390 0.49 (0.45–0.53) 0.50 (0.46–0.54)
 20–29 900 406 0.51 (0.47–0.55) 0.52 (0.48–0.55)
 30–39 2,102 493 0.62 (0.59–0.65) 0.63 (0.60–0.66)
 40–49 5,954 798 1.00 1.00
 50–59 15,237 1,358 1.70 (1.65–1.75) 1.69 (1.64–1.74)
 60–69 25,024 2,227 2.79 (2.71–2.87) 2.71 (2.63–2.78)
 70+ 14,731 3,016 3.78 (3.67–3.89) 3.56 (3.45–3.67)
Race/ethnicity
 White, non-Hispanic 47,447 1,658 1.00 1.00
 Black, non-Hispanic 10,553 1,374 0.83 (0.81–0.85) 0.98 (0.96–1.00)
 Hispanic 5,085 919 0.55 (0.54–0.57) 0.68 (0.66–0.70)
 Asian/Pacific Islander 1,996 968 0.58 (0.56–0.61) 0.64 (0.61–0.67)
Time since first transplant, years
 0–1.99 11,988 1,185
 2–4.99 15,369 1,304 1.10 (1.07–1.13) 1.04 (1.02–1.07)
 5–9.99 19,848 1,631 1.38 (1.34–1.41) 1.22 (1.19–1.25)
 10+ 17,876 1,818 1.53 (1.50–1.57) 1.30 (1.27–1.34)
Transplanted organ (most recent transplant)
 Kidney only 34,078 1,369 1.00 1.00
 Liver only 13,731 1,418 1.04 (1.02–1.06) 0.92 (0.90–0.94)
 Heart only 9,091 1,971 1.44 (1.41–1.47) 1.16 (1.14–1.19)
 Lung only 4,435 2,552 1.86 (1.81–1.92) 1.61 (1.56–1.66)
 Other/multiple 3,746 1,261 0.92 (0.89–0.95) 1.02 (0.99–1.06)
Induction medication (most recent transplant)
 None recorded 15,642 1,535 1.09 (1.07–1.12) 1.00 (0.98–1.03)
 Polyclonal antibodies 14,974 1,404 1.00 1.00
 Anti-interleukin-2 antibodies 12,126 1,495 1.06 (1.04–1.09) 0.97 (0.94–0.99)
 Corticosteroids only 15,434 1,525 1.09 (1.06–1.11) 0.98 (0.95–1.00)
 Other 6,905 1,434 1.02 (0.99–1.05) 1.01 (0.98–1.03)
Baseline maintenance regimen (most recent transplant)
 None recorded 1,045 1,642 1.15 (1.09–1.23) 1.00 (0.94–1.06)
 Cyclosporine and/or azathioprine 12,348 1,610 1.13 (1.11–1.15) 1.06 (1.03–1.08)
 Tacrolimus and/or mycophenolate 40,219 1,423 1.00 1.00
 Other 11,469 1,566 1.10 (1.08–1.12) 0.99 (0.97–1.01)

Notes

Abbreviations: 95%CI, 95% confidence interval; IRR, incidence rate ratio.

*

The multivariable IRRs in the table are mutually adjusted for the other listed characteristics.

Table 3.

Cancer incidence among solid organ transplant recipients in 1995–2003, 2004–2012, and 2013–2021

Cancer outcome Crude incidence rate, per 100,000 person years (N) Age-adjusted IRR (95%CI) Fully adjusted * IRR (95%CI)
1995–2003 2004–2012 2013–2021 2004–2012 vs. 1995–2003 2013–2021 vs. 1995–2003 2004–2012 vs. 1995–2003 2013–2021 vs. 1995–2003
Overall 1,238 (10,560) 1,477 (23,666) 1,595 (30,855) 0.99 (0.96–1.01) 0.93 (0.91–0.95) 0.99 (0.96–1.02) 0.93 (0.90–0.96)
Colorectum 80 (679) 85 (1369) 84 (1620) 0.83 (0.76–0.91) 0.68 (0.62–0.75) 0.84 (0.76–0.93) 0.69 (0.61–0.77)
Lung 171 (1460) 213 (3415) 202 (3910) 0.91 (0.86–0.97) 0.70 (0.66–0.75) 0.93 (0.87–1.00) 0.73 (0.67–0.79)
Breast (female) 153 (515) 171 (1071) 191 (1435) 0.96 (0.86–1.06) 0.97 (0.87–1.07) 0.94 (0.84–1.06) 0.96 (0.84–1.09)
Prostate (male) 206 (1066) 263 (2568) 257 (3044) 0.95 (0.88–1.02) 0.76 (0.71–0.82) 0.99 (0.92–1.08) 0.81 (0.74–0.89)
Kidney 79 (678) 134 (2150) 142 (2746) 1.55 (1.42–1.69) 1.56 (1.43–1.70) 1.44 (1.31–1.59) 1.39 (1.25–1.55)
NHL 194 (1657) 175 (2800) 177 (3419) 0.83 (0.79–0.89) 0.79 (0.74–0.84) 0.84 (0.79–0.91) 0.79 (0.73–0.85)

Notes

Abbreviations: 95%CI, 95% confidence interval; IRR, incidence rate ratio

*

The fully adjusted IRRs include adjustment for sex, attained age, race/ethnicity, transplanted organ, time since first transplant, and induction and baseline maintenance medications (see Table 2 for categories).

Table 3 presents results for individual cancer types. For several cancers (i.e., lung, breast, prostate, and kidney cancers), crude incidence rates showed an increase between 1995–2003 and 2013–2021. However, in models adjusted for attained age, there were significant declines for NHL and cancers of the colorectum, lung, and prostate. In the age-adjusted models, breast cancer showed no significant change between the two calendar periods, while kidney cancer incidence was 56% higher in 2013–2021 than in 1995–2003 (adjusted IRR 1.56, 95%CI 1.43–1.70). Finally, additional multivariable adjustment for other factors did not change the associations between calendar period and cancer risk, except the association for kidney cancer, which was modestly attenuated (adjusted IRR 1.39, 95%CI 1.25–1.55 for 2013–2021 vs. 1995–2003).

Figures 2 and 3 show the calendar trends in age-standardized cancer incidence rates and Supplementary Table 3 presents the corresponding estimates of annual percentage change; for comparison with SOTRs, the figures also depict the trends in general population incidence rates, age-standardized to the SOTR population. For cancer overall (Figure 2), age-standardized rates among SOTRs declined on average by −0.5% per year (95%CI −0.7 to −0.4) across the entire 1995–2021 period.

Figure 2.

Figure 2.

Calendar trends in the overall incidence of cancer. Incidence rates are age-standardized to the 2010 population of solid organ transplant recipient (SOTRs) followed in the Transplant Cancer Match Study. Results are shown for the observed rates in SOTRs (circles), the rates in SOTRs modeled using Joinpoint (solid line), and the rates in the United States general population (dashed line).

Figure 3.

Figure 3.

Calendar trends in the incidence of the selected cancer types. Incidence rates are age-standardized to the 2010 population of solid organ transplant recipient (SOTRs) followed in the Transplant Cancer Match Study. Results are shown for the observed rates in SOTRs (circles), the rates in SOTRs modeled using Joinpoint (solid line), and the rates in the United States general population (dashed line). The panels present results for cancers of the colorectum (panel A), lung (panel B), breast in females (panel C), prostate in males (panel D), and kidney (panel E), and non-Hodgkin lymphoma (panel F). The vertical scale varies across the panels.

Figure 3 shows calendar trends in age-standardized incidence among SOTRs for the six common cancer types. Incidence of two cancers steadily declined across the 1995–2021 period: colorectal cancer (−2.1% per year, Figure 3A) and NHL (−1.2%, Figure 3F). For lung cancer, incidence was flat until 2007 and then declined (−3.4% per year, Figure 3B). Breast cancer incidence did not change significantly over time (Figure 3C). The pattern for prostate cancer was complex, showing alternating periods of decrease and increase, with a decline most recently (−4.0% per year during 2017–2021, Figure 3D). Finally, kidney cancer incidence increased steeply until 1998, increased more moderately by 4.9% per year during 1998–2009, and then was flat during 2009–2021 (Figure 3E).

SIRs are presented in Table 4 as a measure of cancer risk in SOTRs relative to the general population. For cancer overall, the SIR decreased from 1.82 (95%CI 1.79–1.86) in 1995–2003 to 1.66 (1.64–1.67) in 2013–2021 but still showed significantly elevated risk relative to the general population. SIRs likewise declined for colorectal cancer, kidney cancer, and NHL. Nonetheless, during 2013–2021, incidence remained elevated for NHL (SIR 3.40, 95%CI 3.28–3.51) and cancers of the colorectum (1.14, 1.09–1.20), lung (2.02, 1.96–2.09), and kidney (3.88, 3.73–4.02). Incidence was significantly lower than in the general population for breast cancer and prostate cancer during all three calendar periods (Table 4).

Table 4.

Standardized incidence ratios for cancer among solid organ transplant recipients in 1995–2003, 2004–2012, and 2013–2021

Cancer outcome Standardized incidence ratio (95%CI)
1995–2003 2004–2012 2013–2021
Overall 1.82 (1.79–1.86) 1.68 (1.65–1.70) 1.66 (1.64–1.67)
Colorectum 1.24 (1.15–1.34) 1.15 (1.09–1.21) 1.14 (1.09–1.20)
Lung 2.01 (1.91–2.11) 2.20 (2.13–2.28) 2.02 (1.96–2.09)
Breast (female) 0.75 (0.69–0.82) 0.73 (0.69–0.78) 0.72 (0.69–0.76)
Prostate (male) 0.79 (0.75–0.84) 0.78 (0.75–0.81) 0.82 (0.79–0.85)
Kidney 4.44 (4.11–4.79) 4.60 (4.40–4.79) 3.88 (3.73–4.02)
NHL 5.79 (5.52–6.08) 3.81 (3.67–3.96) 3.40 (3.28–3.51)

Notes

Abbreviation: 95%CI, 95% confidence interval

Additional analyses for kidney cancer

Most kidney cancers in SOTRs (80.3%) were diagnosed at localized stage. The increase in kidney cancer incidence over time was present for cancers diagnosed at localized stage (Figure 4A) but not regional/distant stage cancers (Figure 4B). Moreover, the increase in localized kidney cancer was apparent among both recipients of a kidney-only transplant and those who received only non-kidney organs (Figure 4C and 4D). Annual percentage change estimates are presented in Supplementary Table 4).

Figure 4.

Figure 4.

Calendar trends in the incidence of kidney cancer (additional analyses). Incidence rates are age-standardized to the 2010 population of solid organ transplant recipient (SOTRs) followed in the Transplant Cancer Match Study. Results are shown for the observed rates in SOTRs (circles) and the rates in SOTRs modeled using Joinpoint (solid line). The panels present results for localized stage kidney cancer among all SOTRs (panel A), regional/distant stage kidney cancer among all SOTRs (panel B), localized stage kidney cancer among kidney-only recipients (panel C), and localized stage kidney cancer among non-kidney recipients (panel D). The vertical scale varies across the panels.

Among recipients of a first kidney-only transplant, duration of dialysis prior to transplant increased steadily across transplant years (median 1.13 years in 1987 vs. 2.54 years in 2021; Supplementary Table 5). However, an increase in kidney cancer incidence over time was still present in this population when duration of dialysis was added to the full multivariable model that included the variables in Table 2 (adjusted IRR 1.60, 95%CI 1.40–1.83 for 2013–2021 vs. 1995–2003).

Discussion

Between 1995–2003 and 2013–2021, there was a 29% increase in the crude incidence of cancer in the US SOTR population (unadjusted IRR 1.29, 95%CI 1.26–1.32). Importantly, however, the transplant population aged substantially during this period, and after adjustment for changes in attained age, overall cancer incidence actually declined by 7% between the two periods (age-adjusted IRR 0.93, 95%CI 0.90–0.96). Despite this decrease, the overall incidence of cancer remained 66% higher during 2013–2021 than in the general population (SIR 1.66, 95%CI 1.64–1.67), and among the individual cancer types we examined, lung cancer, kidney cancer, and NHL continued to show substantially elevated incidence during this recent period (SIR range 2.02–3.88).

The aging of the SOTR population across the 1995–2021 period (captured by the attained age distribution shown in Figure 1A) reflects improved posttransplant survival (11–14) and a corresponding accumulation of patients followed longer after their transplants (Figure 1B). Older age is a major risk factor for most cancers, due to the lifetime effects of carcinogenic exposures and gradual accumulation of genetic damage (16). For cancer overall and some of the individual cancer types that we examined, adjustment for attained age had a large effect on the association with calendar period, while additional adjustment for other risk factors had no further effect, except for modest attenuation for kidney cancer (Table 3). These analyses indicate that aging of SOTRs is the main explanation for the crude population-level increase in cancer incidence over time.

Other independent risk factors for overall cancer included the elapsed time since first transplant. In addition, lung and heart recipients experienced a greater incidence of cancer, and liver recipients a lower incidence, compared with kidney recipients. These associations likely reflect the effects of duration and intensity of immunosuppression, as the associations with transplanted organ roughly parallel the typical doses and levels of maintenance immunosuppressant medications. In the multivariable analysis, we also observed increased cancer risk associated with maintenance immunosuppression with cyclosporine and/or azathioprine. These medications are considered by the International Agency for Research on Cancer (IARC) to be carcinogenic, in part due to their direct effects on DNA (4). They have largely been replaced over time by tacrolimus and mycophenolate. Of note, IARC recently determined that tacrolimus, which like cyclosporine is a calcineurin inhibitor, is also carcinogenic (5).

What then explains the 7% decline in overall cancer incidence among SOTRs between 1995–2003 and 2013–2021 that was apparent after multivariable adjustment for these factors? To gain further insight, we evaluated calendar trends in cancer incidence using age-standardized rates, which (like model-based adjustment) remove the effect of aging. For overall cancer, the Joinpoint analysis indicated that there was a steady decline of −0.5% per year across the entire 1995–2021 period (Figure 2). Of interest, there was a noticeable jump in incidence in 2021 for overall cancer and some individual cancer types (Figures 2 and 3). However, this increase was based on data from a small subset of cancer registries (Supplementary Table 1) and was not strong enough to materially affect the overall trends. This pattern has also been observed in US general population data and has been attributed to delays in medical care due to the COVID-19 pandemic (17).

The reasons for the overall decline in cancer likely vary across the many individual cancer types that comprise the total. One explanation for some cancers may be a growing tendency among physicians to use lower doses of immunosuppressant medications (e.g., calcineurin inhibitors) (15), taking advantage of improvements in histocompatibility testing and aiming to reduce the risks associated with over-immunosuppression (including cancer). Another explanation could be an increase in the strictness of recipient selection during this period. Beginning in 2007, the US Centers for Medicare and Medicaid Services (CMS) promulgated regulations that required transplant centers to achieve minimally acceptable posttransplant outcomes (15). Changes in selection in response to these regulations may have led to an improvement in overall health among recent SOTRs, although that would have affected cancer incidence only among SOTRs who received their transplants after that date, whereas some cancers that contributed to the trends after 2007 occurred in people transplanted years earlier.

Two additional factors that could have contributed to the overall cancer trend and trends for some specific cancer types should be considered. The comprehensive medical evaluation of candidates for a transplant typically includes cancer screening (18–21). Detection of asymptomatic cancers during the candidate evaluation process, followed by deferral of those patients with cancer from transplantation, likely reduces the subsequent incidence of cancer among people who actually receive a transplant (22). It is therefore possible that improvements over time in pretransplant cancer screening contributed to the declining posttransplant trends we observed. Finally, the decrease in cancer incidence could be due to a decline among SOTRs in the prevalence of major risk factors (e.g., smoking). Unfortunately, we lacked data on these factors and so could not assess their contributions to cancer trends.

With respect to individual cancer types, both colorectal cancer and NHL showed steady declines in incidence among SOTRs during 1995–2021. SOTRs have a modestly elevated incidence of colorectal cancer overall, which may be due in part to underlying medical conditions, carcinogenic effects of immunosuppressant medications, or the immunosuppression itself (6, 23). The decrease in the age-standardized incidence rates for colorectal cancer that we observed among SOTRs closely paralleled the trend in the general population (Figure 3A) and may reflect greater uptake of screening for this cancer over time (24). Among SOTRs, NHL is closely tied to loss of immune control of EBV (25–27), and the declining trend shown in Figure 3F may reflect the changes in immunosuppressant management mentioned above. This hypothesis is supported by the lack of a similar decline in NHL incidence in the general population, among whom the prevalence of immunosuppression is low and where EBV infection is less relevant (28).

For lung cancer, we observed a decrease in age-standardized incidence rates starting in 2007 (Figure 3B). The reason for this change in slope in 2007 is unclear. To some extent, it may reflect more stringent selection of SOTRs based on new CMS regulations starting in 2007, including deferral of individuals with a heavy smoking history or additional pretransplant screening for lung cancer. Lung cancer incidence in the general population also declined over this period (Figure 3B), which is largely attributed to declining smoking prevalence in response to public health measures (29).

Kidney cancer is the only cancer for which we observed an increase in incidence between 1995–2003 and 2013–2021, even after multivariable adjustment (Table 3). Among kidney recipients, most kidney cancers arise in the end-stage native kidneys that are left in situ at the time of transplantation (8). The increase in kidney cancer incidence across calendar periods persisted in our analysis after adjustment for the duration of dialysis prior to transplantation, a known risk factor for posttransplant kidney cancer (8). Notably, most kidney cancers diagnosed among SOTRs were localized stage; the increase over time was limited to this subset; and the increase in localized stage cancers was seen in both kidney-only and non-kidney recipients (Figure 4). Localized stage kidney cancers are often diagnosed incidentally, and the rise in kidney cancer over time among SOTRs could largely be due to increasing use and ease of obtaining abdominal imaging (30). Some of these cancers may have been incidentally detected and may represent instances of over-diagnosis (30).

Breast and prostate cancers are common in SOTRs, but incidence of both cancers is lower among US SOTRs than in the general population (Table 3) (9). This decreased incidence may be caused by screening of transplant candidates for these cancers with mammography and prostate-specific antigen (PSA) testing (22, 31). In the present study, breast cancer incidence was steady over time, but prostate cancer showed a more variable trend with an overall decline across 1995–2021 (Figure 3D). As shown in the figure, this pattern mirrors the trend in prostate cancer incidence seen in the general population, which has been associated in large part with changes in PSA screening recommendations (32, 33).

Our study has important strengths, including its substantial size and population-based coverage of the majority of SOTRs in the US. We systematically evaluated trends for overall cancer and the six most common cancer types. However, we could not individually assess all cancer types, and, because we focused on calendar trends, we could not perform an in-depth analysis of risk factor associations for the included cancers. Another limitation, as noted above, is that we lacked information on certain cancer risk factors and screening. We also did not evaluate changes in maintenance medications after the baseline period and had no data on medication doses or levels.

Given the continuing elevation in cancer incidence among the SOTR population, cancer prevention and screening should remain a priority for transplant providers (34). Most guidelines recommend screening SOTRs for colorectal, breast, and cervical cancers following general population practice. Recommendations regarding PSA screening for prostate cancer are mixed (34), reflecting a lack of consensus on screening in the general population. Counseling for smoking cessation is important, and screening for lung cancer among high-risk individuals (including smokers and lung recipients) can be considered (7, 35). Although SOTRs, especially kidney recipients, have an elevated risk for developing kidney cancer (8), the benefits of screening for this cancer have not been demonstrated (35) and there is a risk of overdiagnosis (30). Finally, SOTRs have a markedly elevated risk for developing squamous cell skin cancer (36). We could not examine this outcome, since this type of cancer is not captured by cancer registries. Nonetheless, because of the elevated risk for squamous cell carcinoma (as well as for other rarer types of skin cancer (37)), SOTRs should be counseled regarding the need to minimize sun exposure and undergo skin cancer screening at least annually (34).

In conclusion, this study demonstrates an encouraging decline during a 27-year period in the overall population-level incidence of cancer among US SOTRs, after accounting for the aging of the SOTR population. However, progress in this regard has been uneven across the cancer types we examined, and the incidence remains elevated compared with the general population overall and for some common cancer types. Importantly, cancer will become an increasing burden among SOTRs as they continue to age. Our findings therefore highlight the importance of efforts by the transplant community to improve cancer prevention, screening, and treatment in the SOTR population.

Supplementary Material

1

Acknowledgments

The authors gratefully acknowledge the support and assistance of the following individuals for providing data from the SRTR (Jon Snyder) and the following cancer registries: the states of Alabama (Justin George), Alaska (David O’Brien), Arkansas (Lunda Lehing), California (Cyllene Morris), Colorado (Jack Finch), Connecticut (Lou Gonsalves), Florida (Brad Wohler), Georgia (Rana Bayakly), Hawaii (Brenda Hernandez), Idaho (Bożena Morawski), Illinois (Lori Koch), Iowa (Charles Lynch), Kentucky (Jaclyn McDowell), Louisiana (Mei-chin Hsieh), Michigan (Georgetta Alverson), Montana (Heather Zimmerman), Nebraska (Lifeng Li), Nevada (Ben Claassen), New Jersey (Xiaoling Niu), New Mexico (Angela Meisner), New York (Tabassum Insaf), North Carolina (Chandrika Rao), North Dakota, Ohio (Emily Bunt), Oklahoma (Meagan Carter), Oregon (Jeff Soule), Pennsylvania (Jim Rubertone), Puerto Rico (Carlos R. Torres), Rhode Island (Junhie Oh), South Carolina (Deborah Hurley), Texas (Paige Miller), Utah (Jen Doherty), Virginia (Shuhui Wang), and the Seattle-Puget Sound area of Washington.

Funding

This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH author(s) are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the author(s) and do not necessarily reflect the views of the US Department of Health and Human Services, NIH, Health Resources and Services Administration, Scientific Registry of Transplant Recipients (SRTR), cancer registries, or their contractors. The SRTR is currently operated under contract number 75R60220C00011 by the Hennepin Healthcare Research Institute, Minneapolis, Minnesota.

The following cancer registries are supported by the SEER Program of the National Cancer Institute: California (contracts HHSN261201000036C, HHSN261201000035C, and HHSN261201000034C), Connecticut (HHSN261201800002I), Hawaii (HHSN261201000037C,N01-PC-35137, and N01-PC-35139), Idaho (HHSN261201800006I), Illinois (75N91021D00006), Iowa (HSN261201000032C, N01-PC-35143, HHSN261201800012I), Kentucky (HHSN261201800013I), New Jersey (75N91021D00009), New York (HHSN26120180005I), Seattle-Puget Sound (HHSN261201800004I, N01 PC-2018-00004), and Utah (HHSN261201800016I). The following cancer registries are supported by the National Program of Cancer Registries of the Centers for Disease Control and Prevention and/or the Surveillance, Epidemiology, and End Results (SEER) Program supported by the Surveillance Research Program in NCI’s Division of Cancer Control and Population Sciences: Alaska (agreement NU58DP007163), California (1U58 DP000807-01), Colorado (U58 DP000848-04), Georgia (5U58DP003875-01), Idaho (1NU58DP007160), Illinois (5NU58DP007162-02-00), Kentucky (1NU58DP007144), Michigan (5U58DP003921-03), Nebraska (NU58DP006278), New Jersey (NU58DP007117), New Mexico (HHSN261201800014I, Task Order HHSN26100001), New York (5 NU58DP007218), North Carolina (U58DP003933), North Dakota (NU58DP006317-05-01), Ohio (NU58DP006284), Oregon (NU58DP007105), Puerto Rico (NU58DP006318), Texas (5U58DP000824-04), and Utah (NU58DP007131). Additional support was provided by the states of California, Colorado, Connecticut, Illinois, Iowa, Montana (5 NU58DP006339-05-00), New Jersey (and Rutgers Cancer Institute), New York (including the Cancer Surveillance Improvement Initiative), Texas, and Fred Hutchinson Cancer Research Center in Seattle, WA.

Abbreviations

95%CI

95% confidence interval

CMS

Centers for Medicare and Medicaid Services

EBV

Epstein-Barr virus

IARC

International Agency for Research on Cancer

IRR

incidence rate ratio

NHL

non-Hodgkin lymphoma

PSA

prostate-specific antigen

SIR

standardized incidence ratio

SOTR

solid organ transplant recipient

SRTR

Scientific Registry of Transplant Recipients

TCM

Transplant Cancer Match

US

United States

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosure statement

The authors do not have any conflicts of interest or external funding to disclose.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

The Transplant Cancer Match Study principal investigator is the custodian for the data. Agreements between the National Cancer Institute, the Health Resources and Services Administration, and participating registries do not allow the investigators to share the data with outside researchers. Interested collaborators can use the study data at the National Cancer Institute under supervision by the principal investigator or can participate in analyses through review of tabulated data.

References

  • 1.Engels EA. Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. Am J Transplant. 2019;19(12):3223–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Huo Z, Li C, Xu X, Ge F, Wang R, Wen Y, Peng H, Wu X, Liang H, Peng G, Li R, Huang D, Chen Y, Zhong R, Cheng B, Xiong S, Lin W, He J, Liang W. Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies. Oncoimmunology. 2020;9(1):1848068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004;77(12):1777–82. [DOI] [PubMed] [Google Scholar]
  • 4.Pharmaceuticals. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon; 2012. [Google Scholar]
  • 5.Cogliano VJ, Corsini E, Fournier A, Nelson HH, Sergi CM, Antunes AMM, Cahoon EK, Chen G, Duarte-Salles T, Engels E, Fu J, Germolec D, Ghiasvand R, Hicks B, Jean-Claude BJ, Jena G, Lerche CM, Li X, Lupattelli A, Ong TP, Vega L, Withrow DR, Boxall ABA, Benbrahim-Tallaa L, de Conti A, Kunzmann A, Pasqual E, Wedekind R, Deng X, Mahamat-Saleh Y, Majidi A, Peruchet-Noray L, Rezende Da Silva J, Suonio E, Viegas S, Zhai Y, Mattock H, Facchin C, Schubauer-Berigan MK, Madia F. Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus. Lancet Oncol. 2025;26(1):15–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Safaeian M, Robbins HA, Berndt SI, Lynch CF, Fraumeni JF Jr., Engels EA. Risk of Colorectal Cancer After Solid Organ Transplantation in the United States. Am J Transplant. 2016;16(3):960–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Triplette M, Crothers K, Mahale P, Yanik EL, Valapour M, Lynch CF, Schabath MB, Castenson D, Engels EA. Risk of lung cancer in lung transplant recipients in the United States. Am J Transplant. 2019;19(5):1478–90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Karami S, Yanik EL, Moore LE, Pfeiffer RM, Copeland G, Gonsalves L, Hernandez BY, Lynch CF, Pawlish K, Engels EA. Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States. Am J Transplant. 2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Engels EA, Pfeiffer RM, Fraumeni JF Jr., Kasiske, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA, Copeland G, Finch JL, Fleissner ML, Goodman MT, Kahn A, Koch L, Lynch CF, Madeleine MM, Pawlish K, Rao C, Williams MA, Castenson D, Curry M, Parsons R, Fant G, Lin M. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891–901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jin F, Vajdic CM, Poynten IM, McGee-Avila JK, Castle PE, Grulich AE. Cancer risk in people living with HIV and solid organ transplant recipients: a systematic review and meta-analysis. Lancet Oncol. 2024;25(7):933–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S, Foutz J, Wainright JL, Snyder JJ, Kasiske BL, Israni AK. OPTN/SRTR 2018 Annual Data Report: Kidney. Am J Transplant. 2020;20 Suppl s1:20–130. [DOI] [PubMed] [Google Scholar]
  • 12.Kwong A, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Noreen SM, Foutz J, Miller E, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant. 2020;20 Suppl s1:193–299. [DOI] [PubMed] [Google Scholar]
  • 13.Colvin M, Smith JM, Hadley N, Skeans MA, Uccellini K, Goff R, Foutz J, Israni AK, Snyder JJ, Kasiske BL. OPTN/SRTR 2018 Annual Data Report: Heart. Am J Transplant. 2020;20 Suppl s1:340–426. [DOI] [PubMed] [Google Scholar]
  • 14.Valapour M, Lehr CJ, Skeans MA, Smith JM, Uccellini K, Goff R, Foutz J, Israni AK, Snyder JJ, Kasiske BL. OPTN/SRTR 2018 Annual Data Report: Lung. Am J Transplant. 2020;20 Suppl s1:427–508. [DOI] [PubMed] [Google Scholar]
  • 15.Pilch NA, Bowman LJ, Taber DJ. Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management. Pharmacotherapy. 2021;41(1):119–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Howlader N, Chen HS, Noone AM, Miller D, Byrne J, Negoita S, Cronin KA, Mariotto AB. Impact of COVID-19 on 2021 cancer incidence rates and potential rebound from 2020 decline. J Natl Cancer Inst. 2024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Chadban SJ, Ahn C, Axelrod DA, Foster BJ, Kasiske BL, Kher V, Kumar D, Oberbauer R, Pascual J, Pilmore HL, Rodrigue JR, Segev DL, Sheerin NS, Tinckam KJ, Wong G, Knoll GA. KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. Transplantation. 2020;104(4S1 Suppl 1):S11–S103. [DOI] [PubMed] [Google Scholar]
  • 19.EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64(2):433–85. [DOI] [PubMed] [Google Scholar]
  • 20.Peled Y, Ducharme A, Kittleson M, Bansal N, Stehlik J, Amdani S, Saeed D, Cheng R, Clarke B, Dobbels F, Farr M, Lindenfeld J, Nikolaidis L, Patel J, Acharya D, Albert D, Aslam S, Bertolotti A, Chan M, Chih S, Colvin M, Crespo-Leiro M, D’Alessandro D, Daly K, Diez-Lopez C, Dipchand A, Ensminger S, Everitt M, Fardman A, Farrero M, Feldman D, Gjelaj C, Goodwin M, Harrison K, Hsich E, Joyce E, Kato T, Kim D, Luong ML, Lyster H, Masetti M, Matos LN, Nilsson J, Noly PE, Rao V, Rolid K, Schlendorf K, Schweiger M, Spinner J, Townsend M, Tremblay-Gravel M, Urschel S, Vachiery JL, Velleca A, Waldman G, Walsh J. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024. J Heart Lung Transplant. 2024;43(10):1529–628.e54. [DOI] [PubMed] [Google Scholar]
  • 21.Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff RM, Patterson CM, Shlobin OA, Smith PJ, Solé A, Solomon M, Weill D, Wijsenbeek MS, Willemse BWM, Arcasoy SM, Ramos KJ. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40(11):1349–79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Doria-Rose VP, Kamineni A, Barrett MJ, Ko CW, Weiss NS. Case-Control Studies of the Efficacy of Screening Tests That Seek to Prevent Cancer Incidence: Results of an Approach That Utilizes Administrative Claims Data That Do Not Provide Information Regarding Test Indication. Am J Epidemiol. 2019;188(4):703–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zwart K, van Kruijsdijk RCM, Angerilli V, Baas MC, Dekker E, Rutgers N, May A, Koopman M, Nagtegaal ID, Bol GM. Risk of deficient mismatch repair colorectal cancer and precursors after kidney transplantation: A nationwide study. Am J Transplant. 2025. [DOI] [PubMed] [Google Scholar]
  • 24.Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54. [DOI] [PubMed] [Google Scholar]
  • 25.Gibson TM, Engels EA, Clarke CA, Lynch CF, Weisenburger DD, Morton LM. Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States. Am J Hematol. 2014;89(7):714–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martinez-Maza O, Hussain SK, Yang J, Chang ET, Engels EA. Risk of lymphoma subtypes after solid organ transplantation in the United States. Br. J Cancer 2013;109(1):280–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Andreone P, Gramenzi A, Lorenzini S, Biselli M, Cursaro C, Pileri S, Bernardi M. Posttransplantation lymphoproliferative disorders. Arch. Intern. Med 2003;163:1997–2004. [DOI] [PubMed] [Google Scholar]
  • 28.Volesky-Avellaneda KD, Morais S, Walter SD, O’Brien TR, Hildesheim A, Engels EA, El-Zein M, Franco EL. Cancers Attributable to Infections in the US in 2017: A Meta-Analysis. JAMA Oncol. 2023;9(12):1678–87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Shiels MS, Graubard BI, McNeel TS, Kahle L, Freedman ND. Trends in smoking-attributable and smoking-unrelated lung cancer death rates in the United States, 1991–2018. J Natl Cancer Inst. 2024;116(5):711–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13. [DOI] [PubMed] [Google Scholar]
  • 31.Ahmed S, Silverberg MJ, Engels EA. Pretransplant screening and lower incidence of breast and prostate cancers among organ transplant recipients in United States. JNCI Cancer Spectr. 2025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Van Blarigan EL, McKinley MA, Washington SL 3rd, Cooperberg MR, Kenfield SA, Cheng I, Gomez SL. Trends in Prostate Cancer Incidence and Mortality Rates. JAMA Netw Open. 2025;8(1):e2456825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Merrill RM. Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States. Cancer Epidemiol. 2024;93:102700. [DOI] [PubMed] [Google Scholar]
  • 34.Acuna SA, Huang JW, Scott AL, Micic S, Daly C, Brezden-Masley C, Kim SJ, Baxter NN. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant. 2017;17(1):103–14. [DOI] [PubMed] [Google Scholar]
  • 35.Dharia A, Boulet J, Sridhar VS, Kitchlu A. Cancer Screening in Solid Organ Transplant Recipients: A Focus on Screening Liver, Lung, and Kidney Recipients for Cancers Related to the Transplanted Organ. Transplantation. 2022;106(1):e64–e5. [DOI] [PubMed] [Google Scholar]
  • 36.Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczek H, Smedby KE. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008--a Swedish population-based study. Int J Cancer. 2013;132(6):1429–38. [DOI] [PubMed] [Google Scholar]
  • 37.Sargen MR, Cahoon EK, Yu KJ, Madeleine MM, Zeng Y, Rees JR, Lynch CF, Engels EA. Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US. JAMA Dermatol. 2022;158(4):414–25. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

Data Availability Statement

The Transplant Cancer Match Study principal investigator is the custodian for the data. Agreements between the National Cancer Institute, the Health Resources and Services Administration, and participating registries do not allow the investigators to share the data with outside researchers. Interested collaborators can use the study data at the National Cancer Institute under supervision by the principal investigator or can participate in analyses through review of tabulated data.

RESOURCES